Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
Vascularity correlates with therapeutic response in liver metastases models
April 22nd, 2003
Vascularity correlates with therapeutic response in liver metastases models. According to recent research published in the British Journal of Cancer, "isolated hepatic perfusion (IHP) with melphalan with or without tumor necrosis factor alpha (TNF-alpha) is currently performed in clinical trials in patients with hepatic metastases. "Previous studies led to the hypothesis that the use of TNF-alpha in isolated limb perfusion causes specific destruction of tumor endothelial cells and thereby induces an increased permeability of tumor vasculature. However, whether TNF-alpha contributes to the therapeutic efficacy in IHP still remains...
Source: Cancer Weekly (2003-04-22)
|
